According to our recent payer coverage analysis for Hepatitis C treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.
To help make sense of this new research, MMIT’s team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.
Payer Coverage: For more than 54% of the covered lives, payer pharmacy benefit formularies do not require step therapy (ST).
Trends: Express Scripts Holding Co. is adding 48 new exclusions on its 2019 National Preferred Formulary, including AbbVie Inc.’s hepatitis C medication Mavyret.